Viewing StudyNCT04055493



Ignite Creation Date: 2024-05-06 @ 1:33 PM
Last Modification Date: 2024-10-26 @ 1:16 PM
Study NCT ID: NCT04055493
Status: RECRUITING
Last Update Posted: 2023-05-15
First Post: 2019-07-22

Brief Title: Adj Marker-adjusted Personalized Therapy Comparing ETRibociclib vs Chemotherapy in Intermediate Risk HRHER2- EBC
Sponsor: West German Study Group
Organization: West German Study Group

Conditions & Keywords Data

Conditions:
Name
Breast Cancer Female
Keywords:
Name View
HR positive View
early breast cancer View
ADAPT View
endocrine therapy View
ribociclib View
intermediate risk View
HER2 negative View